Vita Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $31M

  • Investors
  • 12

Vita Therapeutics General Information

Description

Operator of a cellular therapeutics and cell engineering company intended for the treatment of debilitating neuromuscular diseases and cancers. The company's treatments utilize induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients, enabling clinicians to address the root cause of diseases using truly curative cellular medicines.

Contact Information

Website
www.vitatx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 801 West Baltimore Street
  • Suite 301
  • Baltimore, MD 21201
  • United States
+1 (609)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 801 West Baltimore Street
  • Suite 301
  • Baltimore, MD 21201
  • United States
+1 (609)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vita Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series B) 12-Oct-2022 $31M Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 23-Jun-2021 Completed Pre-Clinical Trials
4. Seed Round 26-Jun-2020 Completed Pre-Clinical Trials
3. Grant 05-Jun-2020 Completed Pre-Clinical Trials
2. Accelerator/Incubator 16-Jul-2019 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2019 Completed Startup
To view Vita Therapeutics’s complete valuation and funding history, request access »

Vita Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-3
Series A-2
Series A-1 7,684,599 $0.001000 $1 $1 1x $1 12.44%
To view Vita Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Vita Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a cellular therapeutics and cell engineering company intended for the treatment of debilitating neuromuscula
Drug Discovery
Baltimore, MD
9 As of 2026

Aarhus, Denmark
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vita Therapeutics Competitors (2)

One of Vita Therapeutics’s 2 competitors is NMD Pharma, a Venture Capital-Backed company based in Aarhus, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NMD Pharma Venture Capital-Backed Aarhus, Denmark
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 2 of 2 competitors. Get the full list »

Vita Therapeutics Patents

Vita Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026207168-A1 Adeno-associated virus (aav) vector for delivery to muscle cells Pending 25-Mar-2025
US-20260009003-A1 Manufacturing of therapeutic satellite cells for treating muscular dystrophy Pending 11-Jul-2022
WO-2024015329-A1 Manufacturing of therapeutic satellite cells for treating muscular dystrophy Inactive 11-Jul-2022
EP-4436615-A1 Immune cell therapy of pd-l1 positive cancers Inactive 26-Nov-2021
US-20250009880-A1 Immune cell therapy of pd-l1 positive cancers Pending 26-Nov-2021 A61K40/31
To view Vita Therapeutics’s complete patent history, request access »

Vita Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vita Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abell Foundation Not-For-Profit Venture Capital Minority
Cedars-Sinai Corporation Minority
Riptide Ventures Angel Group Minority
Solve FSHD Not-For-Profit Venture Capital Minority
Cambrian Bio VC-Backed Company Minority
You’re viewing 5 of 12 investors. Get the full list »

Vita Therapeutics FAQs

  • When was Vita Therapeutics founded?

    Vita Therapeutics was founded in 2019.

  • Where is Vita Therapeutics headquartered?

    Vita Therapeutics is headquartered in Baltimore, MD.

  • What is the size of Vita Therapeutics?

    Vita Therapeutics has 9 total employees.

  • What industry is Vita Therapeutics in?

    Vita Therapeutics’s primary industry is Drug Discovery.

  • Is Vita Therapeutics a private or public company?

    Vita Therapeutics is a Private company.

  • What is Vita Therapeutics’s current revenue?

    The current revenue for Vita Therapeutics is .

  • How much funding has Vita Therapeutics raised over time?

    Vita Therapeutics has raised $65.7M.

  • Who are Vita Therapeutics’s investors?

    Abell Foundation, Cedars-Sinai, Riptide Ventures, Solve FSHD, and Cambrian Bio are 5 of 12 investors who have invested in Vita Therapeutics.

  • Who are Vita Therapeutics’s competitors?

    NMD Pharma and Sarepta Therapeutics are competitors of Vita Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process